Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Paul Ridker Wolfgang Koenig |
| Publication date | October 22, 2010 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |